Enzyme-linked immunosorbent assay for detection ofMycoplasma pneumoniae specific immunoglobulin M

Hirschberg, Lotta; Krook, Aud; Pettersson, C A; Vikerfors, Tomas

doi:10.1007/bf01962354

Cited by 26 publications

(8 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many commercial assays for routine diagnostics were developed and compared to CFA tests. The sensitivity and speci®city range from 71% to 92% and 80% to 98%, respectively [2,8,25,37,40,61,85]. These tests are dif®cult to compare because of dierent tests formats.…”

Section: Complement ®Xation Assaymentioning

confidence: 98%

Respiratory tract infections by Mycoplasma pneumoniae in children: a review of diagnostic and therapeutic measures

Ferwerda

Moll

Groot

2001

European Journal of Pediatrics

126

132

View full text Add to dashboard Cite

show abstract

Section: Complement ®Xation Assaymentioning

confidence: 98%

Respiratory tract infections by Mycoplasma pneumoniae in children: a review of diagnostic and therapeutic measures

Ferwerda

Moll

Groot

2001

European Journal of Pediatrics

126

132

View full text Add to dashboard Cite

show abstract

“…EIAs are more sensitive for detecting acute infection than culture and can be comparable in sensitivity to PCR, provided that a sufficient time has elapsed since infection for antibody to develop and that the patient has a functional immune system. Crude multiantigen preparations, purified proteins (including the P1 adhesin), -capture approaches, purified glycolipids, and synthetic peptides have all been used as targets (22,64,116,190,191,203,303,399,425,445). Patient sera are incubated with the solid-phase antigen, and bound antibodies are visualized by using substrate and enzyme-labeled conjugates directed against the primary antibody.…”

Section: Serologymentioning

confidence: 99%

Mycoplasma pneumoniaeand Its Role as a Human Pathogen

2004

View full text Add to dashboard Cite

Mycoplasma pneumoniae is a unique bacterium that does not always receive the attention it merits considering the number of illnesses it causes and the degree of morbidity associated with it in both children and adults. Serious infections requiring hospitalization, while rare, occur in both adults and children and may involve multiple organ systems. The severity of disease appears to be related to the degree to which the host immune response reacts to the infection. Extrapulmonary complications involving all of the major organ systems can occur in association with M. pneumoniae infection as a result of direct invasion and/or autoimmune response. The extrapulmonary manifestations are sometimes of greater severity and clinical importance than the primary respiratory infection. Evidence for this organism's contributory role in chronic lung conditions such as asthma is accumulating. Effective management of M. pneumoniae infections can usually be achieved with macrolides, tetracyclines, or fluoroquinolones. As more is learned about the pathogenesis and immune response elicited by M. pneumoniae, improvement in methods for diagnosis and prevention of disease due to this organism may occur

show abstract

“…An accurate diagnosis with convalescentphase samples is often made many days after the onset of disease (28). Sensitivity and specificity values are between 55 and 100%, depending on the serological method used and the patient population tested (1,4,8,10,15,18,25). PCR has been shown to offer the potential of increased sensitivity and rapidity compared to other diagnostic tests.…”

mentioning

confidence: 99%

Comparison and Evaluation of Real-Time PCR, Real-Time Nucleic Acid Sequence-Based Amplification, Conventional PCR, and Serology for Diagnosis of Mycoplasma pneumoniae

Templeton¹,

Scheltinga²,

Graffelman³

et al. 2003

J Clin Microbiol

134

View full text Add to dashboard Cite

Mycoplasma pneumoniae is a common cause of community-acquired pneumonia and lower-respiratory-tract infections. Diagnosis has traditionally been obtained by serological diagnosis, but increasingly, molecular techniques have been applied. However, the number of studies actually comparing these assays is limited. The development of a novel duplex real-time PCR assay for detection of M. pneumoniae in the presence of an internal control real-time PCR is described. In addition, real-time nucleic acid sequence-based amplification (NASBA) on an iCycler apparatus is evaluated. These assays were compared to serology and a conventional PCR assay for 106 clinical samples from patients with lower-respiratory-tract infection. Of the 106 samples, 12 (11.3%) were positive by all the molecular methods whereas serology with acute sample and convalescent samples detected 6 (5.6%) and 9 (8.5%), respectively. Clinical symptoms of the patients with Mycoplasmapositive results were compared to those of the other patients with lower-respiratory-tract infections, and it was found that the results for mean lower age numbers as well as the presence of chills, increased erythrocyte sedimentation rate, and raised C-reactive protein levels showed significant differences. Molecular methods are superior for diagnosis of M. pneumoniae, providing more timely diagnosis. In addition, using real-time methods involves less hands-on time and affords the ability to monitor the reaction in the same tube.

show abstract

Enzyme-linked immunosorbent assay for detection ofMycoplasma pneumoniae specific immunoglobulin M

Cited by 26 publications

References 8 publications

Respiratory tract infections by Mycoplasma pneumoniae in children: a review of diagnostic and therapeutic measures

Respiratory tract infections by Mycoplasma pneumoniae in children: a review of diagnostic and therapeutic measures

Mycoplasma pneumoniaeand Its Role as a Human Pathogen

Comparison and Evaluation of Real-Time PCR, Real-Time Nucleic Acid Sequence-Based Amplification, Conventional PCR, and Serology for Diagnosis of Mycoplasma pneumoniae

Contact Info

Product

Resources

About